Ibrutinib for CLL/SLL: Not for Immediate Use at Diagnosis

　　Ibrutinib is a BTK inhibitor indicated for treatment-naïve or relapsed/refractory chronic lymphocytic leukemia(CLL)and small lymphocytic lymphoma(SLL).However,a diagnosis does not mean immediate therapy.CLL/SLL is highly heterogeneous—some patients remain stable for years,and early intervention may unnecessarily expose them to adverse events.

　　For asymptomatic patients with early-stage,inactive disease,the standard approach is“watchful waiting”or active monitoring with regular blood counts,nodal and splenic assessments,and symptom review.Even with high-risk features such as TP53 aberrations or 17p deletion,therapy is not urgent unless disease activity criteria are fulfilled.Watchful waiting is not abandoning treatment;it preserves quality of life while ensuring timely intervention once indications appear.

　　According to the International Workshop on CLL(iwCLL)guidelines,treatment with ibrutinib should be considered when any of the following active disease manifestations​occur:

　　Progressive bone marrow failure:hemoglobin<10 g/dL or platelets<100×10⁹/L,or a declining trend;

　　Massive or progressive lymphadenopathy/splenomegaly:bulky nodes or symptomatic splenomegaly;

　　Rapid lymphocyte proliferation:≥50%increase within 2 months,or lymphocyte doubling time<6 months;

　　Disease-related systemic symptoms:unexplained weight loss,persistent fever,night sweats,or significant fatigue(B symptoms);

　　Autoimmune complications:corticosteroid-refractory autoimmune hemolytic anemia or thrombocytopenia;

　　Extranodal organ involvement:symptomatic or functionally impairing lesions in lung,kidney,skin,etc.

　　After initiation,some patients notice nodal shrinkage or blood count improvement within weeks,though response speed varies.A key point is that transient lymphocytosis​is common early in BTK inhibitor therapy—a hemodynamic shift from blocked lymphocyte trafficking,not disease progression.Counts typically decline over time.Any treatment adjustment should be based on comprehensive evaluation by the treating physician.